Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trialLucia Del Mastro, A Parisi, Mario Giuliano et al.|The Lancet Oncology|2022Cited by 50
PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical OncologyFederica Miglietta, Stefania Gori, Michela Cinquini et al.|The Breast|2022Cited by 16